Singapore, Oct. 7 -- RedHill Biopharma, a US-based specialty biopharmaceutical company, has announced the licensing of Talicia for new Middle East markets in a deal worth potentially $1.8 million plus sales royalty payments.

Under the terms of the agreement, RedHill will receive $500,000 in guaranteed payments, including a $250,000 upfront payment and $250,000 in fixed payments due within 18 months. In addition, RedHill may receive a minimum of $1.3 million in near-term potential milestone payments, as well as tiered royalties up to mid-teens percent on Talicia net sales.

Rick Scruggs, RedHill's Chief Commercial Officer said,"RedHill is committed to expanding patient access to Talicia globally and we now have an excellent opportunity fo...